Sharon E Frey1, Patricia L Winokur2, Heather Hill3, Johannes B Goll3, Paul Chaplin4, Robert B Belshe5. 1. Saint Louis University Medical School, Department of Internal Medicine, United States. Electronic address: freyse@slu.edu. 2. University of Iowa and Iowa City VA Medical Center Health Care System, Department of Internal Medicine, United States. 3. EMMES Corporation, Rockville, MD, United States. 4. Bavarian Nordic GmbH, Martinsried, Germany. 5. Saint Louis University Medical School, Department of Internal Medicine, United States.
Abstract
INTRODUCTION: Reintroduction of Variola major as an agent of bioterrorism remains a concern. Time to seroconversion and plaque reduction neutralizing antibody titers (PRNT) of 1 or 2 standard doses (SD) were compared to a single high dose (HD) of modified vaccinia Ankara (MVA). METHODS:Ninety subjects were randomized 1:1 to receive 1 HD or 2 SD of MVA subcutaneously on Days 0 and 28 in a placebo-controlled trial. Serum was collected for PRNT and ELISA. Subjects were followed for safety for the entire study. RESULTS: The HD was well-tolerated. Using Bavarian Nordic's ELISA, subjects in both groups achieved seroconversion by Study Day 15 (HD) and Day 28 (SD). Before second vaccination, the hazard rate of seroconverting for the HD group was 1.7 times the SD group with a median time for seroconversion of 14 days for both groups. The peak titer of one HD vaccine was superior to one dose of SD vaccine but inferior to the peak titer after the second dose of the SD vaccination regimen. Using Saint Louis University's PRNT, peak titers were 95.8 and 65.2 for the HD and SD groups, respectively, prior to second vaccination. Non-inferiority of the SD group was not established. The proportions of positives were 93.3% (42/45) and 82.2% (37/45) for the HD and SD groups, respectively. The peak titer after two standard doses was superior to that of the HD. CONCLUSIONS: HD MVA was safe and well-tolerated. While the hazard rate for seroconverting was significantly higher in the HD group before second dose, the effect was small as the median time to seroconversion was identical. When comparing PRNT, non-inferiority of one SD was not established and the peak titers were low for both groups. The HD peak response was inferior to the standard two-dose regimen response based on ELISA and PRNT.
RCT Entities:
INTRODUCTION: Reintroduction of Variola major as an agent of bioterrorism remains a concern. Time to seroconversion and plaque reduction neutralizing antibody titers (PRNT) of 1 or 2 standard doses (SD) were compared to a single high dose (HD) of modifiedvaccinia Ankara (MVA). METHODS: Ninety subjects were randomized 1:1 to receive 1 HD or 2 SD of MVA subcutaneously on Days 0 and 28 in a placebo-controlled trial. Serum was collected for PRNT and ELISA. Subjects were followed for safety for the entire study. RESULTS: The HD was well-tolerated. Using Bavarian Nordic's ELISA, subjects in both groups achieved seroconversion by Study Day 15 (HD) and Day 28 (SD). Before second vaccination, the hazard rate of seroconverting for the HD group was 1.7 times the SD group with a median time for seroconversion of 14 days for both groups. The peak titer of one HD vaccine was superior to one dose of SD vaccine but inferior to the peak titer after the second dose of the SD vaccination regimen. Using Saint Louis University's PRNT, peak titers were 95.8 and 65.2 for the HD and SD groups, respectively, prior to second vaccination. Non-inferiority of the SD group was not established. The proportions of positives were 93.3% (42/45) and 82.2% (37/45) for the HD and SD groups, respectively. The peak titer after two standard doses was superior to that of the HD. CONCLUSIONS: HD MVA was safe and well-tolerated. While the hazard rate for seroconverting was significantly higher in the HD group before second dose, the effect was small as the median time to seroconversion was identical. When comparing PRNT, non-inferiority of one SD was not established and the peak titers were low for both groups. The HD peak response was inferior to the standard two-dose regimen response based on ELISA and PRNT.
Authors: Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden Journal: J Infect Dis Date: 2013-03-12 Impact factor: 5.226
Authors: Eric M Mucker; Joseph W Golden; Christopher D Hammerbeck; Jennifer M Kishimori; Michael Royals; Mathew D Joselyn; John Ballantyne; Aysegul Nalca; Jay W Hooper Journal: J Virol Date: 2021-12-01 Impact factor: 6.549
Authors: Chuan Wang; Matthew Hart; Cecilia Chui; Augustine Ajuogu; Iona J Brian; Simone C de Cassan; Persephone Borrow; Simon J Draper; Alexander D Douglas Journal: J Immunol Date: 2016-07-13 Impact factor: 5.422
Authors: Edgar Turner Overton; Steven J Lawrence; Eva Wagner; Katrin Nopora; Siegfried Rösch; Philip Young; Darja Schmidt; Christian Kreusel; Sonja De Carli; Thomas P Meyer; Heinz Weidenthaler; Nathaly Samy; Paul Chaplin Journal: PLoS One Date: 2018-04-13 Impact factor: 3.240
Authors: Edgar Turner Overton; Jack Stapleton; Ian Frank; Shawn Hassler; Paul A Goepfert; David Barker; Eva Wagner; Alfred von Krempelhuber; Garth Virgin; Thomas Peter Meyer; Jutta Müller; Nicole Bädeker; Robert Grünert; Philip Young; Siegfried Rösch; Jane Maclennan; Nathaly Arndtz-Wiedemann; Paul Chaplin Journal: Open Forum Infect Dis Date: 2015-05-05 Impact factor: 3.835
Authors: Julia A Tree; Graham Hall; Peter Rees; Julia Vipond; Simon G P Funnell; Allen D Roberts Journal: Hum Vaccin Immunother Date: 2016-07-02 Impact factor: 3.452
Authors: Richard N Greenberg; Christine M Hay; Jack T Stapleton; Thomas C Marbury; Eva Wagner; Eva Kreitmeir; Siegfried Röesch; Alfred von Krempelhuber; Philip Young; Richard Nichols; Thomas P Meyer; Darja Schmidt; Josef Weigl; Garth Virgin; Nathaly Arndtz-Wiedemann; Paul Chaplin Journal: PLoS One Date: 2016-06-21 Impact factor: 3.752